Tag: SCS

Saluda Medical presents data on 24-month holistic response to spinal cord...

Saluda Medical has announced that Steven Falowski (Argires-Marotti Neurosurgical Associates of Lancaster, Lancaster, USA) recently presented late-breaking 24-month data from the company’s EVOKE study at...

High-frequency SCS demonstrates “substantial improvement” in health-related quality of life outcomes

Nevro Corporation has announced that the complete 12-month results from the SENZA-PDN randomised controlled trial (RCT), including health-related quality of life outcomes in patients with...

High responder rates, substantial pain relief and no explants among key...

Nevro Corporation has announced the results from data presentations at the American Diabetes Association (ADA) 82nd Scientific Sessions (3–7 June 2022, New Orleans, USA) supporting the use of...
senza-nsrbp

High-frequency SCS drives impactful outcomes for non-surgical refractory back pain patients

Following the recent introduction of key data supporting the use of high-frequency spinal cord stimulation (SCS) in the treatment of non-surgical refractory back pain...

Saluda Medical raises US$125m to boost Evoke spinal cord stimulation offering

Saluda Medical has finalised US$125 million in equity financing, with the proceeds being used in part to operationalise and scale commercialisation of the company’s Evoke spinal...

Multiple-modality spinal cord stimulation demonstrates sustained improvement in chronic pain outcomes

A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...

Saluda Medical receives FDA approval for the Evoke spinal cord stimulation...

Saluda Medical has announced that it has received full approval from the US Food and Drug Administration (FDA) for the Evoke spinal cord stimulation (SCS)...

Nevro announces publication of 12-month data on high-frequency SCS for non-surgical...

Nevro Corporation has announced online publication of 12-month data from the SENZA-NSRBP randomised controlled trial (RCT) in Journal of Neurosurgery: Spine. These data show that...

SCS for postlaminectomy syndrome associated with minor reductions in opioid use,...

Spinal cord stimulation (SCS) for postlaminectomy syndrome (PLS) is associated with small, clinically questionable opioid discontinuation and a lower rate of new opioid use...

Medtronic announces FDA approval of spinal cord stimulation therapy for treating...

Medtronic has received US Food and Drug Administration (FDA) approval of its Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator for the treatment of chronic...

Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...

Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...

DTM spinal cord stimulation endurance therapy associated with meaningful pain relief...

Differential Target Multiplexed (DTM) spinal cord stimulation (SCS) endurance therapy provides meaningful pain relief according to three-month data from the DTM-LE trial—the findings of...
spinal cord stimulation patient access

Current gaps and barriers in patient access to spinal cord stimulation

Maricela Schnur (St Luke’s Hospital, Duluth, USA) highlights a handful of socioeconomic disparities, racial differences, and psychological and psychiatric factors that currently present difficulties...

Passive recharge burst spinal cord stimulation provides sustainable improvements in pain...

Passive recharge burst spinal cord stimulation (B-SCS) can alleviate pain intensity, psychological distress, and improve physical function and health-related quality of life out to two years,...
scs diabetic neuropathy

High-frequency SCS takes the stage to relieve chronic pain from diabetic...

Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...

NeoSpine first to offer spinal cord stimulation for treatment of painful...

NeoSpine is now offering spinal cord stimulation (SCS) procedures for the treatment of painful diabetic neuropathy (PDN) via its HFX system—a newly approved nondrug treatment...
nevro senza

Nevro announces FDA approval of high-frequency SCS therapy for painful diabetic...

Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system to treat chronic pain associated with painful diabetic...

Medtronic receives FDA approval for labelling of Intellis platform when using...

Medtronic has announced that the US Food and Drug Administration (FDA) has approved the revised commercial labelling for the Intellis platform with differential target...

Non-surgical refractory back pain patients have better pain outcomes with 10KhZ...

Findings of a randomised, prospective study suggest that non-surgical refractory back pain (NSRBP) patients have better outcomes with 10KhZ spinal cord stimulation (SCS) and...

Abbott launches NeuroSphere myPath digital health app 

Abbott has announced the launch of its NeuroSphere myPath digital health app, designed to track and report patient perceived pain relief and general well-being...

WaveWriter Alpha SCS systems launches in USA

Boston Scientific has announced that its WaveWriter Alpha spinal cord stimulation (SCS) systems will have a limited market release in the USA. The SCS...

New findings suggest patients prefer one-stage SCS screening trial

A new study, published in the journal Neuromodulation, has found that patients show a preference for a one-stage spinal cord stimulation (SCS) screening trial,...